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Abstract
Staphylococcus caprae has been recently classified as a human pathogen, but the incidence of S. caprae in human bone and joint infections
(BJIs) is under-reported. In this study, we report 25 cases of S. caprae BJI, and we review the 31 cases published in the literature. Molecular
techniques and matrix-assisted laser desorption ionization time-of-flight mass spectrometry improved the identification of clinically relevant
S. caprae strains. In this study, 96% of S. caprae BJIs were localized to the lower limbs, and 88% of the cases involved orthopaedic device
infections. S. caprae joint prosthesis infections (JPIs), internal osteosynthesis device infections (I-ODIs) and BJIs without orthopaedic device
infections were recorded in 60%, 28% and 12% of cases, respectively. Ten (40%) S. caprae BJIs were polymicrobial infections. These
infections were associated with past histories of malignancy (p 0.024). Of the 14 bacterial species related to S. caprae BJI, 57% were
staphylococci. I-ODIs were significantly associated with polymicrobial infections (p 0.0068), unlike JPIs, which were monomicrobial
infections (p 0.0344). Treatment with rifampicin and fluoroquinolone was recorded in 40% of cases. Surgical treatment was performed in
76% of cases, e.g. prosthesis removal (36%), osteosynthesis device removal (24%), and surgical debridement (16%). Thirty per cent of cases
were not treated. Relapses were observed mainly in the patients treated by surgical debridement only (p 0.033). In summary, S. caprae BJI is
an underestimated hospital-acquired emerging infection. S. caprae BJI is correlated with infections in orthopaedic devices, which must be
removed to control the infection.
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Introduction
Staphylococcus caprae is a commensal coagulase-negative
staphylococcus that usually colonizes the skin and the mam-
mary glands in goats [1], occasionally causing mastitis [2]. In
humans, commensal S. caprae exists in noses, nails, and skins
[3,4]. Furthermore, S. caprae strains cause commu-
nity-acquired and/or hospital-acquired infections in humans
(Table 1), e.g. acute otitis externa [3,5], peritonitis [6], urinary
tract infections [7,8], pneumonia [9], endocarditis [8], menin-
gitis [10], and many cases of bacteraemia [4,8,9,11–16]. Some
S. caprae strains isolated from goats produce toxic shock
syndrome toxin 1 [17].
The relationship between S. caprae and human bone and
joint infections (BJIs) was first reported in 1997 [3,18].
However, only 31 cases of S. caprae BJI have been reported
[3,11,18–27]. Most S. caprae BJIs result from orthopedic
device infections, including joint prosthesis infections (JPIs) in
21 cases [3,11,19,20,23–26,28] and internal osteosynthesis
device infections (I-ODIs) in two cases [19,21]. Only four
cases of S. caprae BJI were not associated with I-ODIs, i.e.
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three cases of osteitis [3,11] and one case of arthritis [18]. The
presence of an osteosynthesis device was not mentioned in
four cases of S. caprae BJI [22] (Table 1).
The prevalence of S. caprae human infections is often
underestimated by conventional phenotypic identification.
Allignet et al. [19] reported that only five of ten S. caprae
strains in human BJIs are identified by the ID32-staph system
(BioMerieux, Marcy l’Etoile, France). Many clinical S. caprae
strains are incorrectly identified by automated phenotypic
identification systems, including MicroScan (Dade Behring,
West Sacramento, CA, USA), Vitek 2 (BioMerieux), and
Crystal GP (Becton Dickinson, Sparks, MD, USA) [3,29,30].
Molecular techniques have improved the identification of
S. caprae strains [6,12,19,22,31,32], and are useful when the
standard culture tests give negative results [27]. An
innovative tool for bacterial identification in the clinical
microbiology laboratory is matrix-assisted laser desorption
ionization time-of-flight mass spectrometry
(MALDI-TOF MS) [33], which has been recently used for
the rapid and accurate identification of clinical S. caprae
strains [30,34].
In this study, we report 25 cases of S. caprae-associated
osteoarticular infections that were managed in our centres in
the last 6 years. We also review 31 cases of osteoarticular
infections and 75 other human infections caused by S. caprae in
the literature.
Materials and Methods
Study population
We retrospectively reviewed 25 S. caprae BJIs, including
arthritis, osteitis, JPIs and I-ODIs. Sixteen S. caprae BJIs were
recorded in the medical charts of patients managed in the
South-East regional referral centre for BJI in the University
Hospital of Marseille from 2006 to December 2012. This
centre is composed of four orthopaedic surgery units, two
plastic surgery units, and two infectious diseases units. Nine
other S. caprae BJIs were recorded in the University Hospital
of Nimes from January 2007 to December 2012. This centre
contains one orthopaedic surgery unit and one infectious
diseases unit.
All S. caprae BJIs were diagnosed on the basis of past
medical history with clinical evidence of infection, using
biological and/or radiological compliant data, with at least
one positive culture from two or more deep samples obtained
with surgical procedures that excluded the contaminated
bacteria. JPI and I-ODI were classified as early (within
1 month), delayed (2–6 months), and late (after 6 months),
according to the time of onset after surgery [35–37]. We
evaluated each medical history, assessing factors such as
demographic characteristics, open fracture and postoperative
infections, and other risk factors associated with S. caprae BJI,
including cancer, haematological malignancy, systemic or local
corticosteroid treatment, diabetes mellitus, and contact with
goats or sheep. We also recorded the location of infection and
the presence of orthopaedic prostheses or devices. We
individually reviewed the antimicrobial and/or surgical treat-
ment approach used.
We evaluated treatment success as the remission rate at 3,
6 and 12 months after the end of antibiotic treatment.
Recurrent infections were defined by pain and swelling of
the bone or joint, wound drainage, implant site erythema,
induration or oedema, joint pain, joint effusion, fever, purulent
discharge from the wound, sinus tract drainage, and persistent
positive culture from deep samples obtained with surgical
procedures after treatment during follow-up examinations at
the clinic. Treatment failure was defined as: (i) recurrence of
BJI or relapse of infection with the previous microorganism at
any time after the first line of medical and surgical treatment;
(ii) recurrence of the same BJI with a different strain or
different microorganism at any time after the first intervention;
and (iii) death directly caused by sepsis resulting from active BJI
without another known infection.
TABLE 1. Review of 106 cases of Staphylococcus caprae
human infection, including 31 cases of S. caprae osteoarticu-
lar infection
Clinical specimens Case (n) Reference
Colonizing strains 10
Nose 7 Shuttleworth et al. [3],
Ross et al. [4]
Nail 1 Shuttleworth et al. [3]
Skin 2 Shuttleworth et al. [3],
Ross et al. [4]
Pathogenic strains 106
Acute otitis externa 32 Shuttleworth et al. [3],
Roland and Stroman [5]
Peritonitis 3 Shin et al. [6]
Urinary tract infection 4 Kanda et al. [7],
Vandenesch et al. [8]
Pneumonia 1 Barelli et al. [9]
Endocarditis 1 Vandenesch et al. [8]
Bacteraemia 33 Vandenesch et al. [8],
Spellerberg et al. [13],
Barelli et al. [9], Fujita et al. [12],
Ross et al. [4], Kini et al. [16],
Kato et al. [14], Abdul Rahman
et al. [15], Darrieutort-Laffite
et al. [11]
Meningitis 1 Kato et al. [14]
Bone and joint infections 31
Arthritis 1 Elsner et al. [18]
Bone infection without
osteosynthesis device
3 Shuttleworth et al. [3],
Darrieutort-Laffite et al. [11]
Prosthesis 21 Shuttleworth et al. [3], Allignet
et al. [19], Blanc et al. [20],
Arciola et al. [23], Campoccia
et al. [28], Achermann et al. [24],
Roux et al. [25], Bajwa et al. [26],
Darrieutort-Laffite et al. [11]
Osteosynthesis device 2 Allignet et al. [19], Lang et al. [21]
Presence of osteosynthesis
device was not mentioned
4 Sivadon et al. [22]
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This study was approved by the institutional research ethics
board, and each patient gave written informed consent.
Specimen collection and microbiological analysis
Deep samples obtained with surgical procedures, i.e. joint
fluids, crushed tissue, or bone biopsies, were inoculated on 5%
sheep blood, chocolate, Mueller–Hinton, trypticase soy and
MacConkey agar plates (BioMerieux) and incubated at 37°C in
a 5% CO2 atmosphere and in an anaerobic atmosphere for
10 days. Pure bacterial cultures, obtained by picking isolated
colonies, were identified with semi-automated Gram staining
(Aerospray Wiescor apparatus; Elitech, Signes, France), cata-
lase and oxidase activity tests, and the Vitek 2 system
(BioMerieux). Further identification was performed with
MALDI-TOF MS and molecular methods, as previously
described [31,33]. The antibiotic susceptibilities of S. caprae
strains were determined and interpreted according to the
recommendations of the French Society for Microbiology
(http://www.sfm-icrobiologie.org/UserFiles/files/casfm/CASFM_
EUCAST_V1_0_2014(1).pdf). Susceptibility to methicillin was
screened by agar diffusion with cefoxitin disks (BioRad,
Marnes-La-Coquette, France).
Statistical analysis
Data analyses were performed with IBM SPSS Statistics
software v.20.0. The proportions were compared by use of
chi-squared two-tailed tests. A p-value of <0.05 was consid-
ered to be statistically significant.
Results
Clinical characteristics
Of the 25 patients with S. caprae BJIs, 21 (84%) were men,
yielding a male/female ratio of 5.25. The mean age was
58  17 years (range, 18–91 years). Five patients (20%) had
close contact with goats/sheep; these patients included two
farm workers, one sheep breeder, one person who frequented
the farm of his brother, and one person who had been bitten
by a goat (Table 2).
A history of osteosarcoma was observed in three patients
(12%). Two patients (8%) received immunosuppressive ther-
apy and corticosteroid treatment for rheumatoid arthritis.
Four patients (16%) had a body mass index of >30, and two
patients (8%) had diabetes mellitus (Table 2).
Except for one case of spondylodiscitis, all S. caprae BJIs
occurred in the lower limbs, including nine cases in the knee
(36%), four cases in the hip (16%), one case in the femur (4%),
four cases in the tibia (16%), three cases in the ankle (12%),
and three cases in the foot (12%) (Table 2).
S. caprae BJIs were associated with orthopaedic device
infections in 22 cases (88%). Fifteen (60%) JPIs were observed:
eight in the knee, four in the hip, and three in the ankle. Seven
(28%) I-ODIs were observed: four plate or/and screw
infections, two intramedullary nail infections, and one pin
infection (Table 2).
S. caprae BJIs in the absence of orthopaedic device infec-
tions occurred in three (12%) cases, including one case of
spondylodiscitis, one foot infection after trauma, and one
diabetic foot infection (Table 2).
Among the 22 S. caprae BJIs associated with orthopaedic
device infections, one (4%) was identified as an early infection,
two (8%) as delayed infections, and 19 (76%) as late infections,
including four cases (16%) between the sixth month and first
year after device implementation and 15 cases (60%) after the
first year of implementation (Table 1). The mean time of the
diagnosis was 1257  1926 days (median, 633 days; range,
19–7885 days).
Microbiological characteristics
Ten S. caprae BJIs (40%) were polymicrobial infections,
involving up to 14 and two different species of aerobic and
anaerobic bacteria, respectively. Staphylococci were the most
frequently observed (12 cases; 57%), i.e. two Staphylococcus
TABLE 2. Clinical relevance of 25 cases of Staphylococcus
caprae osteoarticular infection in our study
Total number
of cases Proportion (%)
Sex
Female 4 16
Male 21 84
Comorbidities and risk factors
Contact with goats/sheep 5 20
Obesity 4 16
Osteosarcoma 3 12
Corticosteroid treatment 2 8
Diabetes mellitus 2 8
Localization
Knee 9 36
Hip 4 16
Tibia 4 16
Ankle 3 12
Foot 3 12
Femur 1 4
Vertebra 1 4
Classification of orthopaedic
device infections
Early infection (first month) 1 4
Delayed infection (second month
to sixth month)
2 8
Late infection (after sixth month) 19 76
Sixth month to 1 year 4 16
After 1 year 15 60
Orthopaedic device
No orthopaedic device 3 12
Orthopaedic prosthesis 15 60
Knee prosthesis 8 32
Hip prosthesis 4 16
Ankle prosthesis 3 12
Other orthopaedic devices 7 28
Plate or screw 4 16
Intramedullary nails 2 8
Pins 1 4
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aureus and ten coagulase-negative staphylococci (five Staphy-
lococcus epidermidis strains, two Staphylococcus capitis strains,
two Staphylococcus lugdunensis strains, and one Staphylococcus
haemolyticus strain). Other Gram-positive bacteria were Cory-
nebacterium tuberculostearicum in one case, and Streptococcus
mitis in one case. Five Gram-negative bacteria (24%) were
associated with S. caprae BJIs, i.e. Haemophilus parainfluenzae,
Morganella morganii, Serratia marcescens, Stenotrophomonas
maltophilia, and Pseudomonas aeruginosa. We also identified
two anaerobic bacteria associated with S. caprae BJIs, i.e.
Finegoldia magna and Peptinophilus species. Among three
non-device-associated S. caprae BJIs, two were monomicrobial
infections with S. caprae, i.e. one case of vertebral infection
and one case of foot osteitis. Another non-device-associated
S. caprae BJI was a chronic burned-out osteitis localized at the
malleolus that evolved for 5 months after the accident, whose
two deep samples were positive for S. caprae and S. aureus.
We observed 15 monomicrobial S. caprae BJIs, which
included 12 JPIs, one I-ODI, and two cases of osteitis without
orthopaedic device infection. Among 10 polymicrobial S. ca-
prae BJIs, we observed six I-ODIs and four JPIs. S. caprae-asso-
ciated polymicrobial BJIs were linked to a past history of
malignancy (3/3 vs. 7/22, p 0.024). We did not observe any
association between polymicrobial infections and the location
of S. caprae BJIs. I-ODIs were significantly associated with
polymicrobial infections (p 0.0068), unlike JPIs, which were
monomicrobial infections (p 0.0344).
All 25 S. caprae BJI strains were susceptible to vancomycin,
teicoplanin, and doxycycline. A total of 24 strains (96%) were
susceptible to methicillin, clindamycin, ofloxacin, gentamicin,
tobramycin, and co-trimoxazole; 23 strains (92%) were
susceptible to rifampicin and fusidic acid. Only one strain
was susceptible to fosfomycin.
Medical and surgical treatment
All 25 patients were treated with at least one antibiotic active
against S. caprae strains. In sum, eight cases were treated with
three antibiotics, 13 cases with two antibiotics, and four cases
with one antibiotic. In ten cases (40%), rifampicin and
fluoroquinolone were used (Table 3). Six cases (24%) received
only medical treatment (Table 3).
Surgical treatment was performed in 19 cases (76%): four
surgical debridements (16%), six osteosynthesis device remo-
vals (24%), and nine prosthesis removals (36%), followed by
one-stage prosthesis exchange in four cases and two-stage
prosthesis exchange in five cases (Table 3).
Follow-up and relapse
Of the 25 patients with S. caprae BJIs, 23 were followed up until
they had no further relapses, and two were lost to follow-up.
Sixteen patients (70%) were in remission 24 months after the
end of treatment. Seven of 23 patients (30%) experienced
treatment failure: three (13%) patients relapsed during the first
line of treatment, and four (17%) relapsed after the end of
treatment. No S. caprae BJI patients died during the study
period. Relapse was significantly associated with surgical
debridement only, without orthopaedic device removal [3/4
vs. 4/19, p 0.033, relative risk (RR) = 11]. Four of ten
polymicrobial BJIs failed to respond to antibiotic treatment
adapted to the bacteria initially identified, and S. caprae was
re-isolated from deep samples with surgical procedures that
excluded contaminating bacteria.
Discussion
In this article, we report 25 S. caprae BJIs that were followed
up at our reference centres and another associated reference
centre over the last 6 years. To our knowledge, 31 S. caprae
BJIs have been reported [3,11,18–27] since the first recogni-
tion of the involvement of S. caprae in BJIs in 1997 [3,18]. The
low incidence of reported S. caprae BJIs may be a result of the
lack of rapid and accurate tools with which to identify S. caprae
strains in the clinical microbiology laboratory
[6,12,19,22,31,32]. Some automated identification systems fail
to identify S. caprae if the database contains insufficient
information on S. caprae strains [3,29,38]. MALDI-TOF MS is
an alternative molecular identification tool [30,33] for the
rapid and accurate identification of S. caprae clinical strains,
and should be used to update the current database [34,39].
Among 386 S. caprae isolates reported in the literature, 17
of 22 were well identified by API Staph [7,9,13,15,18,20,23,40],
TABLE 3. Treatment of 25 cases of Staphylococcus caprae
osteoarticular infection in our study
Treatment strategy Effective Percentage
Antibiotic treatment
Three antibiotics 8 32
Vancomycin + rifampicin + fluoroquinolone 4 16
Teicoplanin + rifampicin + fluoroquinolone 2 8
Teicoplanin + rifampicin + fusidic acid 1 4
Rifampicin + fluoroquinolone + co-trimoxazole 1 4
Two antibiotics 13 52
Rifampicin + fluoroquinolone 10 40
Vancomycin + imipenem 1 4
Co-trimoxazole + fluoroquinolone 1 4
Co-trimoxazole + doxycycline 1 4
One antibiotic 4 16
Vancomycin 2 8
Doxycycline 1 4
Co-trimoxazole 1 4
Hyperbaric oxygen therapy 2 8
Medical treatment alone 6 24
Surgical treatment 19 76
Surgical debridement 4 16
Joint prosthesis removal 9 36
One-stage prosthesis exchange 4 16
Two-stage prosthesis exchange 5 20
Other osteosynthesis removal 6 24
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16 of 153 were well identified by ID32 Staph [8,10,14,18–
20,23,38,41], 64 of 85 were well identified by Vitek
[3,16,29,30,39,41], none of 15 were well identified by Micro-
scan [3,29], nine were well identified by Phoenik [30], five of
eight were well identified by 16S PCR (plus two false positives)
[6,13,27,41], seven were well identified by soda gene sequenc-
ing [6,22], four were well-identified by tuf gene sequencing
[6,41], 65 of 74 were well identified by ribotyping 16S–23S
printer [4,8,23,40], 17 of 19 were well identified by internal
transcribed spacer PCR [12,42], 17 of 19 were well identified
by multiplex-PCR [32], four of five were well identified by
pulsed-field gel electrophoresis [15], one was well identified by
rpoB gene sequencing [31], one was well identified by autolysin
gene sequencing [43], and 88 of 89 were well identified by
MALDI-TOF MS [30,34,39,41]. The identification of S. caprae
clonal types by pulsed-field gel electrophoresis and ribotyping
has been reported [4,15].
Physical contact with goats or sheep was reported in one
case of S. caprae sacro-ileitis [11]. No more than five patients
(20%) with S. caprae BJIs in our study had close contact with
goats or sheep in their medical history. In total, 22 of 25 (88%)
S. caprae BJIs were associated with orthopaedic devices,
suggesting that these infections were related to medical care
and contracted in hospitals.
The nosocomial origin of human infection by S. caprae has
been noted in the literature. One such example was the
outbreak of clonal S. caprae strains resistant to methicillin in
six infants in a neonatal intensive-care unit [4]. S. caprae also
colonized the nares of ten infants hospitalized in the same unit,
and the hand of a care provider in that unit [4]. Many other
hospital-acquired S. caprae infections have been reported,
including bacteraemia in a 2-day-old neonate [13], central
line-associated bacteraemia in a patient after chemotherapy for
acute myelogenous leukaemia [14], three cases of peritonitis
after continuous ambulatory peritoneal dialysis [6], and a case
of meningitis following intraspinal device infection [10].
The relationship between BJI and nosocomial S. caprae
infection is difficult to prove. Elsner et al. [18] reported an
intra-articular S. caprae infection following an arthroscopic
cruciate ligament repair. Blanc et al. also reported a case of hip
JPI caused by S. caprae at the fourth month after prosthesis
implant [20].
Furthermore, we observed comorbidity in our patients, i.e.
obesity in four cases, past history of osteosarcoma in three
cases, rheumatism arthritis with immunosuppressive treatment
in two cases, and diabetes mellitus in two cases. These
comorbidities have been reported in only two of 31 cases of
S. caprae osteoarticular infection, i.e. one case of liver
transplant and one case of corticosteroid treatment associated
with chemotherapy and radiotherapy for lymphoma [3,11].
To date, S. caprae infection has been associated with I-ODI
in 45 of 56 (80%) S. caprae BJIs, i.e., 25 cases in our study and
31 previously published cases. In particular, S. caprae BJIs
affected joint prostheses in 64% of cases, i.e. 15 cases in our
study and 21 cases in the literature [3,11,19,20,23–26,28].
S. caprae I-ODIs were recorded in 16% of cases, i.e. seven
cases in this study and two cases in the literature [19,21].
Finally, S. caprae infections in the absence of I-ODI were
observed in only 12% of cases, i.e. three cases in this study and
four previously reported cases. The infection source was not
mentioned in the other four cases of S. caprae BJI [22].
Almost all S. caprae BJIs occurred in the lower limbs (24 of
25 cases, 96%). This finding was consistent with 12 of 14 (86%)
S. caprae BJIs in the literature [3,11,18–20]. Nevertheless,
infections occur in other parts of the body, causing one case of
spondylodiscitis in our study, two cases of elbow prosthesis
infection [3,24], and one case of mastoiditis [3].
In this study, 40% of S. caprae BJIs were polymicrobial
infections. The high prevalence of polymicrobial infections has
been reported in ten cases of JPI (55%) of 18 cases of BJI
associated with S. caprae [3,11,18–20]. Trauma or malignancy
as underlying osteosarcoma was known as a risk of polymi-
crobial infections in nine of ten cases of traumatic fractures [3]
and in 21 of 55 cases of infections after pelvic resection for
bone tumours [44].
Ninety six per cent of S. caprae strains in our study were
susceptible to methicillin; only one strain was resistant.
Methicillin-resistant S. caprae strains have been observed in
many cases of human infection [4,7,14]. Despite the low rate of
antibiotic-resistant S. caprae strains, we observed a high
treatment failure rate in our study, i.e. seven S. caprae BJIs
(30%). Two of seven patients with reported S. caprae BJIs
were not treated successfully [3]. This high treatment failure
rate (21%) was recently reported in a series of 28 BJIs caused
by S. lugdunensis, in which only two strains were methicil-
lin-resistant [45].
S. caprae is a commensal, coagulase-negative staphylococcus
of the goat and human skin flora [1–4], and it becomes a
human pathogen in many community-acquired or/and hospi-
tal-acquired infections [3–16,18,19,21–27]. As compared with
S. aureus and other coagulase-negative staphylococci, only a
few virulence factors have been recognized in S. caprae. The
well-known factors involved in the pathogenicity of S. caprae
were: (i) the ability to adhere to human tissues through the
production of autolysin or fibronectin-binding proteins coded
by the altC gene [19,46]; and (ii) the fact that the presence of
the ica operon provides the ability to form a biofilm on the
bone and/or orthopaedic osteosynthesis devices [19,46], on
the catheter line, or on the intraspinal device [10], protecting
the bacterium from the immune system and antibiotics [19,46].
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The staphylococcal enterotoxin A and staphylococcal entero-
toxin-like toxin type P have been identified in S. caprae [47].
To control chronic S. caprae BJI, our data suggest that
infected orthopaedic devices should be removed (four relapses
in the groups of 19 device removals vs. three relapses after
four surgical debridements without device removal, p 0.033,
RR 11).
Conclusion
S. caprae osteoarticular infection is an underestimated hospi-
tal-acquired emerging infectious disease. Its lack of detection in
clinical laboratories may be attributable to there being
insufficient S. caprae clinical strains in the databases used for
conventional phenotypic identification. Molecular identification
methods and MALDI-TOF MS should be improved to identify
S. caprae osteoarticular infections. S. caprae osteoarticular
infections are often associated with polymicrobial infections
and orthopaedic devices, which must be removed to control
infections embedded in biofilm.
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